Basal cell carcinoma
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
O manu'a ma'i e a'afia ai le pa'u o le isu i se tagata matua e masani ona maua i le Basal cell carcinoma. O le isu ose nofoaga masani e tupu ai lea ituaiga o kanesa o le pa'u.
Basal cell carcinoma e ono iai ni tuaoi fa'aletonu ma papala.
Basal cell carcinoma e mafai ona fa'aseseina o le pa'u.
References
Basal cell carcinoma (BCC) o le ituaiga sili ona taatele o le kanesa o le pa'u. O le susulu o le la o le mafuaaga autu lea. Toeitiiti lava o mataupu uma a le BCC o loʻo faʻaalia ai le faʻamalosi Hedgehog faʻailoga i le suʻesuʻega mole. O togafitiga eseese e avanoa ma filifilia e fa'atatau i le fa'alavelave toe tupu, taua o le fa'asaoina o aano, mea e fiafia i ai ma'i, ma le tele o fa'ama'i.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinomas o le ituaiga sili ona taatele o le kanesa o le pa'u i tagata matutua pa'ulelei e 50 tausaga ma luga atu. O lo'o fa'atupula'ia lo latou aofa'i i le lalolagi atoa, aemaise ona o le fa'aalia o le la. O nisi tulaga fa'aletagata e mafai ona fa'atosina ai tagata i le atia'e o nei kanesa a'o laiti. Basal cell carcinomas ese'ese i le ogaoga, e amata mai i manu'a papa'u po'o nodular e faigofie ona togafitia i manu'a sili atu e mana'omia ai talanoaga i 'au fa'afoma'i fa'apitoa. E fa'alagolago le fa'amasani ile ono toe fo'i mai o le kanesa po'o lona mafai ona fa'aleagaina aano o lo'o lata ane. O le taotoga o le togafitiga masani mo le tele o mataupu, faʻamautinoa le aveeseina saʻo ma le maualalo o avanoa e toe foʻi ai. O auala fa'aitiitia fa'alavelave e mafai ona togafitia lelei manu'a papa'u.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Ole togafitiga muamua ole BCC ole taotoga. Mo le maualuga o le lamatiaga poʻo le faʻaauau pea o le BCC, aemaise lava i vaega ogaoga, e fautuaina le taotoga micrographically pulea. O ma'i e maualalo le lamatiaga o le BCC papa'u e ono mafaufau i togafitiga fa'apitoa po'o ni auala fa'aleagaina. E aoga tele le togafitiga o le photodynamic mo BCCs nodular papa'u ma maualalo le lamatia. Mo le BCC fa'apitonu'u po'o le metastatic BCC, fa'agata Hedgehog (vismodegib, sonidegib) e fautuaina. Afai o iai fa'ama'i fa'asolo po'o le le fa'apalepale i le Iniseti Hedgehog, e mafai ona mafaufauina le immunotherapy fa'atasi ma le anti-PD1 antibody (cemiplimab) . Radiotherapy o se filifiliga lelei mo gasegase e le mafai ona faia se taotoga, aemaise lava tagata matutua. E mafai ona iloiloina le electrochemotherapy pe afai e le o se filifiliga le taotoga poo le radiotherapy.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
O a'afiaga e a'afia ai le fa'aalia i le malamalama ultraviolet, togafitiga fa'avevela, fa'ataga umi i le arsenic ma le le lelei o le fa'aogaina o le tino (fa'ata'ita'iga o totoga toto). O le fa'aalia i le malamalama o le UV a'o laiti e matua afaina lava.
A mae'a su'esu'ega ile biopsy, ole togafitiga e masani lava ile tipi'esea. E mafai ona faia lenei mea e ala i le tipiina faigofie pe afai e laʻititi le kanesa; Afai e le itiiti le kanesa, e masani ona fautuaina le taotoga Mohs.
Ole basal cell carcinoma e a'afia ile 32% ole kanesa uma ile lalolagi. O kanesa o le pa'u e ese mai i le melanoma, e tusa ma le 80% o kanesa sela. I totonu o le Iunaite Setete, e tusa ma le 35% o tama pa'epa'e ma le 25% o tama'ita'i papa'e e a'afia i le basal cell carcinoma i se taimi o latou olaga.
○ Suiga ma Togafiti
#Dermoscopy
#Skin biopsy
#Mohs surgery